Template:Pyrazinamide: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
Chetan Lokhande (talk | contribs)
nocaptcha
4,484 edits
No edit summary
Gerald Chi (talk | contribs)
CMEAdmin, Bureaucrats, bureaucrats, editnews, exportpages, interwiki, nocaptcha, nukepages, smwadministrator, Administrators, Widget editors
17,702 edits
mNo edit summary
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
| style="padding: 0 5px; font-size: 100%; background:#696969" align=center | <span style="color:WHITE;"> '''[[Pyrazinamide|Pyrazinamide]]'''</span>
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Pyrazinamide|{{fontcolor|#6C7B8B|Pyrazinamide}}]]'''''
|-
|-
! style="padding: 0 5px; font-size: 85%; background:WHITE" align=left | FDA Package Insert (MIKART<sup>®</sup>)
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | PYRAZINAMIDE<sup>®</sup> FDA Package Insert
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide description|Description]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide description|Description]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide clinical pharmacology|Clinical Pharmacology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide clinical pharmacology|Clinical Pharmacology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide microbiology|Microbiology]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide indications and usage|Indications and Usage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide indications and usage|Indications and Usage]]
Line 19: Line 17:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide overdosage|Overdosage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide overdosage|Overdosage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide clinical studies|Clinical Studies]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide dosage and administration|Dosage and Administration]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide how supplied|How Supplied]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide how supplied|How Supplied]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide labels and packages|Labels and Packages]]
|-
|-
|}
|}

Latest revision as of 02:53, 4 January 2014

Pyrazinamide
PYRAZINAMIDE® FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Retrieved from "https://www.wikidoc.org/index.php?title=Template:Pyrazinamide&oldid=923950"